Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and i...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461173/ |